NYU Data Catalog

NYU Dataset

Authors: Andrew T. Timberlake

Casey Griffin

Carrie L. Heike

Anne V. Hing

25 more author(s)...
Description: This dataset was collected to study the genetic cause of craniofacial microsomia (CFM), which is the second most common congenital facial anomaly. In this study, they performed whole-exome or genome sequencing of 146 kindreds with sporadic (n = 138) or familial (n = 8) CFM. This is identified as a highly significant burden of loss of function variants in SF3B2, which is the most prevalent genetic cause...
Subject: Genomics
Access Rights: Free to All

NYU Dataset

Authors: Eileen M. Boyle

Shayu Deshpande

Ruslana Tytarenko

Cody Ashby

19 more author(s)...
Description: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder. It is associated with a high-risk of progression to multiple myeloma (MM). For this study, they performed targeted sequencing on 82 patients. The results showed fewer NRAS and FAM46C mutations with SMM, which is consistent with their role as drivers of the transition to MM. They also analyzed the change in clonal structure over...
Subject: Cancer

Genomics
Access Rights: Free to All

Author Approval Required

Authors: Graham Jackson
Description: Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI) was a randomized controlled trial which recruited 4420 patients in the United Kingdom who were newly diagnosed with symptomatic or non-secretory multiple myeloma to study the...
Subject: Cancer

Genomics
Access Rights: Author Approval Required
Local Expert: Gareth J. Morgan

Alternate Title(s): CoMMpass
Description: The Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile (CoMMpass) trial is a longitudinal observational study sponsored by the Multiple Myeloma Research Foundation (MMRF) which follows adult patients with newly diagnosed and symptomatic myeloma over a 10 year period. The study began in 2011 and has enrolled 1154 participants across the United States, Canada, and Spain. Study...
Subject: Cancer

Genomics
Access Rights: Free to All

Application Required
Local Expert: Gareth J. Morgan

Authors: Graham Jackson
Description: Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI) was a randomized controlled trial which recruited 4420 adult patients in the United Kingdom who were newly diagnosed with symptomatic or non-secretory multiple myeloma to study...
Subject: Cancer

Genomics

Risk Factors
Access Rights: Application Required

Author Approval Required
Local Expert: Gareth J. Morgan

Alternate Title(s): MMGS
Authors: Irene M. Ghobrial
Description: Sequencing data was collected from adult patients with a diagnosis of myeloma, monoclonal gammopathy of undetermined significance (MGUS), or smoldering myeloma in order to define the genomic characteristics of tumor cells and the tumor microenvironment (including immune cells and peripheral blood) associated with the progression of multiple myeloma. The sequencing data released to dbGaP in 2019...
Subject: Cancer

Genomics
Access Rights: Free to All

Application Required
Local Expert: Gareth J. Morgan

NYU Dataset

Authors: Ze-Yan Zhang

Yingwen Ding

Ravesanker Ezhilarasan

Tenzin Lhakhang

9 more author(s)...
Description: Although targeted cancer therapies have been successful, their efficacies are limited by the development of resistance driven by clonal evolution within tumors. This study developed a single-cell barcoding approach to comprehensively trace clonal dynamics and capture live lineage-coupled resistant cells for in-depth multi-omics analysis and functional exploration. They showed that heterogeneous clones,...
Subject: Cancer

Genomics
Access Rights: Free to All